Magdent Logo
Try MED now

Published case study of a surgical workflow in an inflammatory environment

Surgical Workflow

Disclaimer: Magdent MED is CE marked for enhancing osseointegration. The protocol described below refers to surgical peri-implant tissue maintenance and is based on published clinical and preclinical evidence. This indication is considered off-label. The clinician is responsible for complying with local regulations and ethical frameworks when applying this protocol in daily practice.

Research: ‘Emerging locally delivered antimicrobial and immunomodulatory approaches’, Periodontology 2000, Alberto Monje.

Emerging locally delivered antimicrobial and immunomodulatory approaches for the prevention/treatment of peri-implant diseases

1. Case Selection and Pre-Surgical Considerations

Use the MED in implant cases where enhanced early healing, improved osseo-integration, soft-tissue support, or modulation of inflammation may be beneficial:

  • Standard implant placement
  • Compromised bone quality (osteoporosis, diabetes, smoking)
  • Post-extraction implants
  • Inflammatory environments where additional biologic support is desirable (without claiming disease treatment)

Contraindications:

  • Submerged-healing protocols
  • Situations requiring immediate loading
  • Patient cannot maintain soft-tissue access to the device

2. Implant Placement

  1. Position the implant crestal or slightly supra-crestal. The MED cannot be covered by soft tissue.
  2. Achieve primary stability as per normal surgical protocol.
  3. Irrigate thoroughly to remove bone fragments and debris from the implant chamber.
  4. Confirm no sharp edges or interference that would prevent MED seating.

3. MED Activation (Outside the Mouth)

  1. Remove the MED vial from the sterile tray.
  2. Place the vial into the activation socket.
  3. Press the activation button:
    • Blue blinking for ~3 seconds = activation
    • Blue solid light = ready for use (10 seconds)
  4. Once activated, remove the MED and transfer directly using a 1.25 mm hex driver.

4. MED Placement

  1. Ensure implant chamber is dry and clean.
  2. Seat the MED with the 1.25 mm hex driver, keeping alignment with implant long axis.
  3. Tighten by hand only until passive seating.
  4. Apply restorative torque up to 10 Ncm. Do not exceed torque to avoid damaging electronics.
  5. Reposition soft tissue around the MED and suture as preferred.
  6. Confirm no occlusal contact with opposing dentition.

5. Immediate Post-Op Instructions

  • The MED is active for 30 days.
  • The device can remain in place until restoration.
  • Avoid electric toothbrushes during the first 30 days, but encourage gentle brushing around the MED to maintain soft tissue health.
  • If a provisional denture is used, ensure a relief space around the device.

6. Follow-Up Protocol

At 2 weeks:

  • Inspect tissue maturation, early keratinization, and absence of inflammation.
  • Verify device is fully seated.

At 4 weeks (30 days):

  • Replace the MED if extended biologic support is desired.
  • Take a baseline radiograph for early bone remodeling evaluation.
  • A 2nd MED may be recommended in moderate to severe inflammatory cases, or when clinical findings at 30 days indicate that extended support would be beneficial.

This is an optional step and should be determined according to the initial severity and the tissue response following the first MED. If a 2nd MED is used, repeat the procedures described in Sections 4 and 5 accordingly.

At 8–12 weeks:

  • Assess implant stability (ISQ recommended).
  • Proceed with restorative phase if healing trajectory is satisfactory.
  • Radiographic comparison to confirm bone density improvements.

7. Biological Rationale (from Periodontology 2000)

This section is optional for clinicians but useful to justify the protocol.

The Periodontology 2000 review highlights emerging host-modulating approaches that target:

  • Chronic inflammatory cycles
  • macrophage dysregulation
  • tissue breakdown and osteoclast activity

PEMF aligns with this category by:

  • modulating cytokines (↓ TNF-α, ↓ IL-1, ↑ IL-10)
  • supporting resolution of inflammation
  • encouraging bone formation through osteoblast activation
  • influencing pathogenic biofilm behavior

These mechanisms justify MED use as an adjunct to conventional implant surgery, not as a stand-alone disease therapy.

Contact Us

Let us know how we can support. We're here to provide support and answers to your clinical or technical questions.

All submissions are responded to within 24 hours.